Compare DRD & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | HAE |
|---|---|---|
| Founded | 1895 | 1971 |
| Country | South Africa | United States |
| Employees | 3410 | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | N/A | 1996 |
| Metric | DRD | HAE |
|---|---|---|
| Price | $26.51 | $67.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $32.63 | ★ $84.13 |
| AVG Volume (30 Days) | 232.5K | ★ 879.1K |
| Earning Date | 08-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $39.23 | N/A |
| Revenue Next Year | $30.12 | $5.23 |
| P/E Ratio | ★ $15.32 | $32.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.08 | $47.32 |
| 52 Week High | $39.37 | $87.32 |
| Indicator | DRD | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 70.70 |
| Support Level | $26.07 | $48.98 |
| Resistance Level | $30.99 | $86.72 |
| Average True Range (ATR) | 0.91 | 2.73 |
| MACD | -0.05 | 1.36 |
| Stochastic Oscillator | 20.03 | 95.35 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.